Obama's New Limits On Corporate Tax Dodging Don't Go Far Enough

New U.S. Treasury Department rules meant to curb a controversial scheme for dodging corporate taxes may not go far enough, analysts say. 

The regulations announced on Monday appeared to be aimed at kneecapping Pfizer’s plan to merge with Irish rival Allergan and reincorporate in Ireland. This would allow the New York-based pharmaceutical giant to take advantage of Ireland's low corporate tax rate when accessing the cash it has stashed overseas. Deals like these are known as a “corporate inversion.”